The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl B

Carl Borrebaeck

Professor

Carl B

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

Author

  • Carl A K Borrebaeck
  • Ann-Christin Malmborg
  • Mats Ohlin

Summary, in English

Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.

Department/s

  • Department of Immunotechnology

Publishing year

1993

Language

English

Pages

477-479

Publication/Series

Immunology Today

Volume

14

Issue

10

Document type

Journal article

Publisher

Elsevier

Status

Published

ISBN/ISSN/Other

  • ISSN: 0167-5699